Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Engels

Showing results (71-80 of 100) with videos related to

Pageof 10
Sort By:
Journal of Chemotherapy (Florence, Italy)|June 23, 2010
Efficacy and safety of sorafenib in advanced hepatocellular carcinoma under daily practice conditionsM W Welker, N Lubomierski, C Gog, et al.
The Journal of Pathology|March 6, 2007
Dynamic intracellular survivin in oral squamous cell carcinoma: underlying molecular mechanism and potential as an early prognostic markerK Engels, S K Knauer, D Metzler, et al.
Endocrine-Related Cancer|December 3, 2005
Methylation of estrogen receptor beta promoter correlates with loss of ER-beta expression in mammary carcinoma and is an early indication marker in premalignant lesionsA Rody, U Holtrich, C Solbach, et al.
Gastrointestinal Endoscopy|June 28, 2001
Bullous colon lesions in a patient with bullous pemphigoidE M Sachsenberg-Studer, U Runne, T Wehrmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 30, 2005
Medicinal cannabis in oncology practice: still a bridge too far?Floris A de Jong, Frederike K Engels, Ron H J Mathijssen, et al.
British Journal of Clinical Pharmacology|March 12, 2025
Methotrexate toxicity and glucarpidase: A call for dose optimizationArjen Koppen, Maaike A Sikma, Frederike K Engels, et al.
British Journal of Clinical Pharmacology|June 29, 2025
Reply to: 'Methotrexate toxicity and glucarpidase: A call for dose optimization'Arjen Koppen, Maaike A Sikma, Frederike K Engels, et al.
Clinical Pharmacology and Therapeutics|April 30, 2004
Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxelFrederike K Engels, Albert J Ten Tije, Sharyn D Baker, et al.
Journal of Pharmaceutical and Biomedical Analysis|September 7, 2007
Pitfalls of the application of microdialysis in clinical oncology: controversial findings with docetaxelW J Loos, W C Zamboni, F K Engels, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2011
Therapeutic drug monitoring for the individualization of docetaxel dosing: a randomized pharmacokinetic studyFrederike K Engels, Walter J Loos, Jessica M van der Bol, et al.
Pageof 10

Showing results (71-80 of 100) with videos related to

Sort By:
Pageof 10
Journal of Chemotherapy (Florence, Italy)|June 23, 2010
Efficacy and safety of sorafenib in advanced hepatocellular carcinoma under daily practice conditionsM W Welker, N Lubomierski, C Gog, et al.
The Journal of Pathology|March 6, 2007
Dynamic intracellular survivin in oral squamous cell carcinoma: underlying molecular mechanism and potential as an early prognostic markerK Engels, S K Knauer, D Metzler, et al.
Endocrine-Related Cancer|December 3, 2005
Methylation of estrogen receptor beta promoter correlates with loss of ER-beta expression in mammary carcinoma and is an early indication marker in premalignant lesionsA Rody, U Holtrich, C Solbach, et al.
Gastrointestinal Endoscopy|June 28, 2001
Bullous colon lesions in a patient with bullous pemphigoidE M Sachsenberg-Studer, U Runne, T Wehrmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 30, 2005
Medicinal cannabis in oncology practice: still a bridge too far?Floris A de Jong, Frederike K Engels, Ron H J Mathijssen, et al.
British Journal of Clinical Pharmacology|March 12, 2025
Methotrexate toxicity and glucarpidase: A call for dose optimizationArjen Koppen, Maaike A Sikma, Frederike K Engels, et al.
British Journal of Clinical Pharmacology|June 29, 2025
Reply to: 'Methotrexate toxicity and glucarpidase: A call for dose optimization'Arjen Koppen, Maaike A Sikma, Frederike K Engels, et al.
Clinical Pharmacology and Therapeutics|April 30, 2004
Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxelFrederike K Engels, Albert J Ten Tije, Sharyn D Baker, et al.
Journal of Pharmaceutical and Biomedical Analysis|September 7, 2007
Pitfalls of the application of microdialysis in clinical oncology: controversial findings with docetaxelW J Loos, W C Zamboni, F K Engels, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2011
Therapeutic drug monitoring for the individualization of docetaxel dosing: a randomized pharmacokinetic studyFrederike K Engels, Walter J Loos, Jessica M van der Bol, et al.
Pageof 10